See the DrugPatentWatch profile for vascepa

Vascepa Discount: How Long Will It Last?

Vascepa, a prescription medication used to treat high triglycerides, has been making headlines with its discounted price. But how long will this discount last? To answer this question, let's dive into the details.

Patent Expiration

According to DrugPatentWatch.com, Vascepa's patent is set to expire in 2025. This means that once the patent expires, other pharmaceutical companies will be able to manufacture and sell generic versions of the medication, which could potentially drive down the price.

Discount Programs

Currently, Vascepa is available under a discount program called the Vascepa Savings Program. This program offers eligible patients a discount of up to $100 per month on their Vascepa prescription. However, it's unclear how long this program will be available.

Manufacturer's Commitment

Amarin Corporation, the manufacturer of Vascepa, has committed to maintaining the discount program until at least 2023. However, it's unclear whether the company will continue the program beyond that date.

Government Programs

Patients who are eligible for government programs such as Medicare Part D or Medicaid may also be able to access Vascepa at a discounted rate. These programs are subject to change, but they can provide a more affordable option for patients who need the medication.

Conclusion

While the Vascepa discount program is currently available, it's unclear how long it will last. The patent expiration in 2025 could lead to the introduction of generic versions of the medication, which could drive down the price. Patients who are eligible for the discount program should take advantage of it while it's available, and those who are not eligible may want to explore other options, such as government programs or generic versions of the medication.

Highlight

"The Vascepa Savings Program is a program designed to help eligible patients access Vascepa at a reduced cost. The program is subject to change or termination at any time."

Source: Amarin Corporation

Sources:

1. DrugPatentWatch.com
2. Amarin Corporation (manufacturer of Vascepa)
3. Medicare.gov (Medicare Part D information)
4. Medicaid.gov (Medicaid information)